[{"id":"c8879055-5cfc-4980-bb0d-ebf82077c424","acronym":"FOENIX-MBC2 TAS-120-201","url":"https://clinicaltrials.gov/study/NCT04024436","created_at":"2021-01-18T19:45:26.836Z","updated_at":"2024-07-02T16:35:00.592Z","phase":"Phase 2","brief_title":"A Study of TAS-120 in Patients With Metastatic Breast Cancer","source_id_and_acronym":"NCT04024436 - FOENIX-MBC2 TAS-120-201","lead_sponsor":"Taiho Oncology, Inc.","biomarkers":" HER-2 • PD-L1 • FGFR2","pipe":" | ","alterations":" HER-2 amplification • HER-2 negative • FGFR1 amplification • FGFR2 amplification","tags":["HER-2 • PD-L1 • FGFR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 amplification • HER-2 negative • FGFR1 amplification • FGFR2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fulvestrant • Lytgobi (futibatinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 168","initiation":"Initiation: 08/30/2019","start_date":" 08/30/2019","primary_txt":" Primary completion: 05/31/2023","primary_completion_date":" 05/31/2023","study_txt":" Completion: 07/05/2024","study_completion_date":" 07/05/2024","last_update_posted":"2024-05-29"},{"id":"6c758fa1-b102-4d99-aa19-27558b9979c8","acronym":"MegaMOST","url":"https://clinicaltrials.gov/study/NCT04116541","created_at":"2021-01-18T20:07:18.206Z","updated_at":"2024-07-02T16:35:12.639Z","phase":"Phase 2","brief_title":"A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors.","source_id_and_acronym":"NCT04116541 - MegaMOST","lead_sponsor":"Centre Leon Berard","biomarkers":" KRAS • BRAF • ALK • FLT3 • NRAS • ROS1 • NTRK2 • HRAS • CDKN2A • NF1 • AXL • CCND1 • CDK4 • PTPN11 • SMAD4 • RAF1 • FLT1 • CDK6 • CCND3 • TYRO3 • NTRK","pipe":" | ","alterations":" KRAS mutation • EGFR mutation • BRAF mutation • NRAS mutation • BRAF V600 • FGFR1 amplification • CDKN2A deletion • HRAS mutation • PTPN11 mutation • CCND1 amplification • KRAS amplification • BRAF amplification","tags":["KRAS • BRAF • ALK • FLT3 • NRAS • ROS1 • NTRK2 • HRAS • CDKN2A • NF1 • AXL • CCND1 • CDK4 • PTPN11 • SMAD4 • RAF1 • FLT1 • CDK6 • CCND3 • TYRO3 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • EGFR mutation • BRAF mutation • NRAS mutation • BRAF V600 • FGFR1 amplification • CDKN2A deletion • HRAS mutation • PTPN11 mutation • CCND1 amplification • KRAS amplification • BRAF amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • Tafinlar (dabrafenib) • Alecensa (alectinib) • Cabometyx (cabozantinib tablet) • Stivarga (regorafenib) • Kisqali (ribociclib) • Ayvakit (avapritinib) • siremadlin (HDM201)"],"overall_status":"Recruiting","enrollment":" Enrollment 455","initiation":"Initiation: 01/28/2020","start_date":" 01/28/2020","primary_txt":" Primary completion: 02/01/2026","primary_completion_date":" 02/01/2026","study_txt":" Completion: 11/01/2026","study_completion_date":" 11/01/2026","last_update_posted":"2024-03-27"},{"id":"45391173-bfa1-492f-828d-d0cb5112e61f","acronym":"","url":"https://clinicaltrials.gov/study/NCT03238196","created_at":"2021-01-17T17:26:50.151Z","updated_at":"2024-07-02T16:35:21.276Z","phase":"Phase 1","brief_title":"Fulvestrant, Palbociclib and Erdafitinib in ER+/HER2-/FGFR-amplified Metastatic Breast Cancer","source_id_and_acronym":"NCT03238196","lead_sponsor":"Vanderbilt-Ingram Cancer Center","biomarkers":" HER-2 • ER • FGFR2 • FGFR1 • FGFR4 • FGF23","pipe":" | ","alterations":" HER-2 negative • FGFR1 amplification • FGFR3 amplification • FGFR4 amplification • FGFR amplification","tags":["HER-2 • ER • FGFR2 • FGFR1 • FGFR4 • FGF23"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • FGFR1 amplification • FGFR3 amplification • FGFR4 amplification • FGFR amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • Balversa (erdafitinib) • fulvestrant"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 35","initiation":"Initiation: 08/18/2017","start_date":" 08/18/2017","primary_txt":" Primary completion: 04/30/2021","primary_completion_date":" 04/30/2021","study_txt":" Completion: 09/25/2024","study_completion_date":" 09/25/2024","last_update_posted":"2024-02-01"},{"id":"e9fbe660-e738-46c7-9c2a-9818bd84d26c","acronym":"","url":"https://clinicaltrials.gov/study/NCT04936295","created_at":"2021-06-23T17:52:35.212Z","updated_at":"2024-07-02T16:36:28.767Z","phase":"Phase 2","brief_title":"Fulvestrant Plus Anlotinib in HR(+)/HER2(-) Metastatic Breast Cancer With FGFR Mutation","source_id_and_acronym":"NCT04936295","lead_sponsor":"Sun Yat-sen University","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive • HER-2 negative • FGFR1 amplification • FGFR mutation","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • FGFR1 amplification • FGFR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Focus V (anlotinib) • fulvestrant"],"overall_status":"Recruiting","enrollment":" Enrollment 61","initiation":"Initiation: 06/16/2021","start_date":" 06/16/2021","primary_txt":" Primary completion: 06/01/2023","primary_completion_date":" 06/01/2023","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2021-06-23"},{"id":"16a0661f-04b5-48f9-87e8-3e9d14716323","acronym":"","url":"https://clinicaltrials.gov/study/NCT00958971","created_at":"2021-01-17T17:55:20.778Z","updated_at":"2024-07-02T16:36:37.100Z","phase":"Phase 2","brief_title":"Safety and Efficacy of TKI258 in FGFR1 Amplified and Non-amplified Metastatic HER2 Negative Breast Cancer","source_id_and_acronym":"NCT00958971","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative • FGFR1 amplification","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • FGFR1 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dovitinib (TKI258)"],"overall_status":"Completed","enrollment":" Enrollment 43","initiation":"Initiation: 07/01/2009","start_date":" 07/01/2009","primary_txt":" Primary completion: 03/01/2011","primary_completion_date":" 03/01/2011","study_txt":" Completion: 03/01/2011","study_completion_date":" 03/01/2011","last_update_posted":"2020-12-19"},{"id":"91d2c7e7-7017-45f1-805f-8e73462eafcd","acronym":"","url":"https://clinicaltrials.gov/study/NCT01283945","created_at":"2021-01-18T05:12:34.871Z","updated_at":"2024-07-02T16:36:51.882Z","phase":"Phase 1/2","brief_title":"Study of Oral Lucitanib (E-3810), a Dual VEGFR-FGFR Tyrosine Kinase Inhibitor, in Patients With Solid Tumors","source_id_and_acronym":"NCT01283945","lead_sponsor":"Institut de Recherches Internationales Servier","biomarkers":" FGFR1 • KDR • VEGFA • FLT1","pipe":" | ","alterations":" FGFR1 amplification","tags":["FGFR1 • KDR • VEGFA • FLT1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR1 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lucitanib (E 3810)"],"overall_status":"Completed","enrollment":" Enrollment 134","initiation":"Initiation: 07/01/2010","start_date":" 07/01/2010","primary_txt":" Primary completion: 09/01/2016","primary_completion_date":" 09/01/2016","study_txt":" Completion: 05/04/2017","study_completion_date":" 05/04/2017","last_update_posted":"2020-01-03"},{"id":"4e06d46a-253b-484d-a0a2-bca662c63ece","acronym":"","url":"https://clinicaltrials.gov/study/NCT01004224","created_at":"2021-01-17T17:13:53.960Z","updated_at":"2024-07-02T16:36:54.872Z","phase":"Phase 1","brief_title":"A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies","source_id_and_acronym":"NCT01004224","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" FGFR2 • FGFR3","pipe":" | ","alterations":" FGFR1 amplification • FGFR2 mutation • FGFR2 amplification • FGFR3 mutation • FGFR3 amplification","tags":["FGFR2 • FGFR3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR1 amplification • FGFR2 mutation • FGFR2 amplification • FGFR3 mutation • FGFR3 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Truseltiq (infigratinib)"],"overall_status":"Completed","enrollment":" Enrollment 208","initiation":"Initiation: 12/11/2009","start_date":" 12/11/2009","primary_txt":" Primary completion: 10/08/2018","primary_completion_date":" 10/08/2018","study_txt":" Completion: 10/08/2018","study_completion_date":" 10/08/2018","last_update_posted":"2019-10-04"},{"id":"7911579f-d9ce-4a7c-80e3-eecd3f5c1c20","acronym":"","url":"https://clinicaltrials.gov/study/NCT01868022","created_at":"2021-01-18T08:21:31.110Z","updated_at":"2024-07-02T16:36:56.798Z","phase":"Phase 1","brief_title":"Study to Evaluate GSK3052230 in Combination With Paclitaxel and Carboplatin, or Docetaxel or as Single Agent in Subjects With Solid Malignancies and Deregulated Fibroblast Growth Factor (FGF) Pathway Signaling","source_id_and_acronym":"NCT01868022","lead_sponsor":"GlaxoSmithKline","biomarkers":" FGF2","pipe":" | ","alterations":" FGFR1 amplification • FGFR1 expression","tags":["FGF2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR1 amplification • FGFR1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • paclitaxel • docetaxel • pemetrexed • FP-1039"],"overall_status":"Completed","enrollment":" Enrollment 65","initiation":"Initiation: 10/09/2013","start_date":" 10/09/2013","primary_txt":" Primary completion: 10/24/2017","primary_completion_date":" 10/24/2017","study_txt":" Completion: 10/24/2017","study_completion_date":" 10/24/2017","last_update_posted":"2019-08-19"},{"id":"9f53334d-5aa1-43fc-b5fd-f596e79c499e","acronym":"","url":"https://clinicaltrials.gov/study/NCT01948141","created_at":"2021-01-18T08:49:51.923Z","updated_at":"2024-07-02T16:37:21.269Z","phase":"Phase 2","brief_title":"Nintedanib in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Up to Two Previous Chemotherapy Regimens","source_id_and_acronym":"NCT01948141","lead_sponsor":"Roswell Park Cancer Institute","biomarkers":" FGFR1","pipe":" | ","alterations":" FGFR1 amplification","tags":["FGFR1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR1 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e nintedanib"],"overall_status":"Completed","enrollment":" Enrollment 6","initiation":"Initiation: 01/30/2014","start_date":" 01/30/2014","primary_txt":" Primary completion: 08/16/2016","primary_completion_date":" 08/16/2016","study_txt":" Completion: 08/16/2016","study_completion_date":" 08/16/2016","last_update_posted":"2017-06-08"},{"id":"34b9c1f0-9514-4521-99d2-b19d1ac14a1c","acronym":"BARIS","url":"https://clinicaltrials.gov/study/NCT01349296","created_at":"2021-01-18T05:30:41.745Z","updated_at":"2024-07-02T16:37:31.819Z","phase":"Phase 1","brief_title":"BIBF 1120 and RAD001 in Solid Tumors - Phase I","source_id_and_acronym":"NCT01349296 - BARIS","lead_sponsor":"University of Cologne","biomarkers":" FGFR1","pipe":" | ","alterations":" FGFR1 amplification","tags":["FGFR1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR1 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e everolimus • nintedanib"],"overall_status":"Completed","enrollment":" Enrollment 18","initiation":"Initiation: 07/01/2012","start_date":" 07/01/2012","primary_txt":" Primary completion: 10/01/2014","primary_completion_date":" 10/01/2014","study_txt":" Completion: 05/01/2016","study_completion_date":" 05/01/2016","last_update_posted":"2016-05-20"}]